MK-1045 Non-Hodgkin Lymphoma Phase 2 Trial, Merck

Merck registered a new Phase 2 clinical trial for MK-1045, an investigational drug, in Non-Hodgkin Lymphoma patients. The trial is listed on ClinicalTrials.gov with identifier NCT07519772. This registration makes the study publicly available and fulfills transparency obligations under FDAAA 801.\n\nAffected parties including clinical investigators, trial sponsors, and institutional review boards should note the trial registration. Patients seeking investigational treatments may benefit from reviewing available eligibility criteria and study locations on the ClinicalTrials.gov listing.